Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, and Affymetrix Inc. (NASDAQ: AFFX) announced today that Affymetrix has granted Epigenomics non-exclusive access to Affymetrix microarray technology to develop and market microarray-based in-vitro diagnostic (IVD) tests for oncology and other indications.
